Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer

OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, E Sun, Kim, Tae-Joong, Lee, Yoo-Young, Choi, Chel Hun, Lee, Jeong-Won, Kim, Byoung-Gie, Bae, Duk-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944013/
https://www.ncbi.nlm.nih.gov/pubmed/27329194
http://dx.doi.org/10.3802/jgo.2016.27.e46
_version_ 1782442690597617664
author Paik, E Sun
Kim, Tae-Joong
Lee, Yoo-Young
Choi, Chel Hun
Lee, Jeong-Won
Kim, Byoung-Gie
Bae, Duk-Soo
author_facet Paik, E Sun
Kim, Tae-Joong
Lee, Yoo-Young
Choi, Chel Hun
Lee, Jeong-Won
Kim, Byoung-Gie
Bae, Duk-Soo
author_sort Paik, E Sun
collection PubMed
description OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospective review of the medical records was performed on 99 recurrent EOC patients who underwent SCS at the Samsung Medical Center between January 2002 and December 2013. For follow-up after primary treatment, patients were routinely assessed by CA-125 levels every 3 months and computed tomography (CT) scan (or magnetic resonance imaging [MRI]) every 6 months for first 3 years, and by CA-125 every 6 months and CT scan (or MRI) every 12 months thereafter. RESULTS: The first recurrence was initially identified by either CA-125 elevation (n=41, 41.4%) or by imaging study (n=58, 58.6%). None of the patients showed the symptoms as initial sign of recurrence. There were higher percentages of extra-pelvic recurrence (87.8%) and multiple recurrences (78.0%) in the group diagnosed by CA-125 elevation. The proportion of no residual disease after SCS was comparably lower in the CA-125 group (22.0% vs. 72.4%). There were 19 cancer-associated deaths (19.2%) within a median follow-up period of 67 months. The group diagnosed by imaging had better overall survival from initial diagnosis (OS1), overall survival after SCS (OS2), progression-free survival after the initial treatment (PFS1) and progression-free survival after SCS compared to those of the CA-125 group (PFS2). CONCLUSION: EOC patients with recurrence initially detected by imaging study showed better survival outcomes than patients diagnosed by CA-125 elevation.
format Online
Article
Text
id pubmed-4944013
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-49440132016-09-01 Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer Paik, E Sun Kim, Tae-Joong Lee, Yoo-Young Choi, Chel Hun Lee, Jeong-Won Kim, Byoung-Gie Bae, Duk-Soo J Gynecol Oncol Original Article OBJECTIVE: The aim of this study was to compare survival outcomes in two groups of patients with recurrent epithelial ovarian cancer (EOC) with initial recurrence detection by cancer antigen 125 (CA-125) elevation or imaging, and underwent secondary cytoreductive surgery (SCS). METHODS: A retrospective review of the medical records was performed on 99 recurrent EOC patients who underwent SCS at the Samsung Medical Center between January 2002 and December 2013. For follow-up after primary treatment, patients were routinely assessed by CA-125 levels every 3 months and computed tomography (CT) scan (or magnetic resonance imaging [MRI]) every 6 months for first 3 years, and by CA-125 every 6 months and CT scan (or MRI) every 12 months thereafter. RESULTS: The first recurrence was initially identified by either CA-125 elevation (n=41, 41.4%) or by imaging study (n=58, 58.6%). None of the patients showed the symptoms as initial sign of recurrence. There were higher percentages of extra-pelvic recurrence (87.8%) and multiple recurrences (78.0%) in the group diagnosed by CA-125 elevation. The proportion of no residual disease after SCS was comparably lower in the CA-125 group (22.0% vs. 72.4%). There were 19 cancer-associated deaths (19.2%) within a median follow-up period of 67 months. The group diagnosed by imaging had better overall survival from initial diagnosis (OS1), overall survival after SCS (OS2), progression-free survival after the initial treatment (PFS1) and progression-free survival after SCS compared to those of the CA-125 group (PFS2). CONCLUSION: EOC patients with recurrence initially detected by imaging study showed better survival outcomes than patients diagnosed by CA-125 elevation. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016-09 2016-05-09 /pmc/articles/PMC4944013/ /pubmed/27329194 http://dx.doi.org/10.3802/jgo.2016.27.e46 Text en Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Paik, E Sun
Kim, Tae-Joong
Lee, Yoo-Young
Choi, Chel Hun
Lee, Jeong-Won
Kim, Byoung-Gie
Bae, Duk-Soo
Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title_full Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title_fullStr Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title_full_unstemmed Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title_short Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
title_sort comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944013/
https://www.ncbi.nlm.nih.gov/pubmed/27329194
http://dx.doi.org/10.3802/jgo.2016.27.e46
work_keys_str_mv AT paikesun comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT kimtaejoong comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT leeyooyoung comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT choichelhun comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT leejeongwon comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT kimbyounggie comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer
AT baeduksoo comparisonofsurvivaloutcomesafterrecurrencedetectedbycancerantigen125elevationversusimagingstudyinepithelialovariancancer